All In Biotech

Drug Trial Radar · NCT03586869

QUILT-3.080: NANT Pancreatic Cancer Vaccine

QUILT-3.080: Phase 1B/2 Trial Of The NANT Pancreatic Cancer Vaccine As Treatment For Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-Of-Care Therapy

Last checked: Nov 20, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

3

Actual

Start

Jul 17, 2018

Primary completion

Apr 17, 2019

Study completion Aug 1, 2019

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Jul 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.

Conditions

  • Pancreatic Cancer

Interventions

  • Aldoxorubicin HClDrug

    Aldoxorubicin Hydrochloride

  • ALT-803Biological

    Recombinant human super agonist interleukin-15 (IL-15) complex

  • ETBX-011Biological

    Ad5 \[E1-, E2b-\]-CEA

  • ETBX-021Biological

    Ad5 \[E1-, E2b-\]-HER2

  • ETBX-051Biological

    Ad5 \[E1-, E2b-\]-Brachyury

  • ETBX-061Biological

    Ad5 \[E1-, E2b-\]-MUC1

  • GI-4000Biological

    RAS yeast

  • GI-6207Biological

    Carcinoembryonic Antigen (CEA) yeast

  • GI-6301Biological

    Brachyury yeast

  • haNK for infusionBiological

    NK-92 \[CD16.158V, ER IL-2\]

  • bevacizumabBiological

    Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal

  • CapecitabineDrug

    5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

  • CyclophosphamideDrug

    2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

  • FluorouracilDrug

    5-fluoro-2,4 (1H,3H)-pyrimidinedione

  • LeucovorinDrug

    L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

  • nab-PaclitaxelDrug

    Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

  • OxaliplatinDrug

    cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

  • AvelumabBiological

    Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody

  • SBRTProcedure

    Stereotactic Body Radiation Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Up to 230 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.